Integrative single-cell transcriptomics and mendelian randomization identifies BTN3A2 as a shared protective factor in Behçet’s disease and inflammatory bowel disease - Top-Institutions - MDSpire

Integrative single-cell transcriptomics and mendelian randomization identifies BTN3A2 as a shared protective factor in Behçet’s disease and inflammatory bowel disease

  • By

  • Qinjin Dai

  • Yuelan Wu

  • Wenbo Geng

  • Mengna Li

  • Wanyun Zhang

  • Yuxian Lai

  • Pei Zhang

  • Chunjiang Zhou

  • Yinuo Wang

  • Qingfeng Cao

  • Xiang Luo

  • Yujie Lai

  • Changwei Huang

  • Peizeng Yang

  • June 24, 2026

  • 0 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    The Johns Hopkins Hospital
    The Johns Hopkins Hospital

    Baltimore, Maryland

    Key Differentiators

    • Rheumatology

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Rheumatology
    • Gastroenterology

Original Source(s)

Integrative single-cell transcriptomics and mendelian randomization identifies BTN3A2 as a shared protective factor in Behçet’s disease and inflammatory bowel disease

  • by Qinjin Dai, Yuelan Wu, Wenbo Geng, Mengna Li, Wanyun Zhang, Yuxian Lai, Pei Zhang, Chunjiang Zhou, Yinuo Wang, Qingfeng Cao, Xiang Luo, Yujie Lai, Changwei Huang, Peizeng Yang

  • June 24, 2026

Related Content

GLP-1 Analog Use is Associated With Improved Disease Course in Inflammatory Bowel Disease: A Report from the Epi-IIRN

Therapeutic potential of Janus kinase inhibitors for the management of fibrosis in inflammatory bowel disease

Uncovering the therapeutic potential of anti-tuberculoid agent Isoniazid in a model of microbial-driven Crohn’s disease